Prise en charge thérapeutique et suivi des spondylarthrites
12.07.2015 • Views
Share Embed Flag

Prise en charge thérapeutique et suivi des spondylarthrites

Prise en charge thérapeutique et suivi des spondylarthrites

Prise en charge thérapeutique et suivi des spondylarthrites

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
umfcs.u.bordeaux2.fr

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

<strong>Prise</strong> <strong>en</strong> <strong>charge</strong> thérapeutique <strong>et</strong> <strong>suivi</strong> <strong>des</strong> <strong>spondylarthrites</strong>154. Askling J, Klareskog L, Blomqvist P,Fored M, Feltelius N. Risk for malignantlymphoma in ankylosing spondylitis: anationwide Swedish case-control study. AnnRheum Dis 2006;65(9):1184-7.155. Winthrop KL. Update on tuberculosis andother opportunistic infections associated withdrugs blocking tumour necrosis factor α. AnnRheum Dis 2005;64(Suppl 4):iv29-30.156. Strangfeld A, Listing J. Bacterial andopportunistic infections during anti-TNFtherapy. Best Pract Res Clin Rheumatol2006;20(6):1181-95.157. Mark<strong>en</strong>son J. Saf<strong>et</strong>y and efficacy of thebiologic response modifiers. Am J Orthop2007;36(3 Suppl):15-9.158. Call<strong>en</strong> JP. Complications and adversereactions in the use of newer biologic ag<strong>en</strong>ts.Semin Cutan Med Surg 2007;26(1):6-14.163. McLeod C, Bagust A, Boland A, Dag<strong>en</strong>aisP, Dickson R, Dundar Y, <strong>et</strong> al. Adalimumab,<strong>et</strong>anercept and infliximab for the treatm<strong>en</strong>t ofankylosing spondylitis: a systematic review andeconomic evaluation. Health Technol Assess2007;11(28).164. Bansback NJ, Ara R, Barkham N,Br<strong>en</strong>nan A, Fraser AD, Conway P, <strong>et</strong> al.Estimating the cost and health statusconsequ<strong>en</strong>ces of treatm<strong>en</strong>t with TNFantagonists in pati<strong>en</strong>ts with psoriatic arthritis.Rheumatology 2006;45(8):1029-38.165. National Institute for Health and ClinicalExcell<strong>en</strong>ce. Adalimumab for the treatm<strong>en</strong>t ofpsoriatic arthritis. NICE technology appraisalguidance 125 2007. [consulté le 27-8-2007].166. Tan AL, Marzo-Ortega H, O'Connor P,Fraser A, Emery P, McGonagle D. Efficacy ofanakinra in active ankylosing spondylitis: aclinical and magn<strong>et</strong>ic resonance imagingstudy. Ann Rheum Dis 2004;63(9):1041-5.159. Ag<strong>en</strong>ce française de sécurité sanitaire<strong>des</strong> produits de santé. Prév<strong>en</strong>tion <strong>et</strong> prise <strong>en</strong><strong>charge</strong> <strong>des</strong> tuberculoses surv<strong>en</strong>ant sous anti-TNFα. Saint-D<strong>en</strong>is: AFSSAPS; 2005.160. Boon<strong>en</strong> A, van der Heijde D, Sever<strong>en</strong>sJL, Bo<strong>en</strong>dermaker A, Landewé R, Braun J, <strong>et</strong>al. Markov model into the cost-utility over fiveyears of <strong>et</strong>anercept and infliximab comparedwith usual care in pati<strong>en</strong>ts with activeankylosing spondylitis. Ann Rheum Dis2006;65(2):201-8.161. Kobelt G, Andlin-Sobocki P,Maksymowych WP. The cost-effectiv<strong>en</strong>ess ofinfliximab (Remicade®) in the treatm<strong>en</strong>t ofankylosing spondylitis in Canada. J Rheumatol2006;33(4):732-40.162. Kobelt G, Sobocki P, Sieper J, Braun J.Comparison of the cost-effectiv<strong>en</strong>ess ofinfliximab in the treatm<strong>en</strong>t of ankylosingspondylitis in the United Kingdom based ontwo differ<strong>en</strong>t clinical trials. Int J Technol AssessHealth Care 2007;23(3):368-75.167. Koh WH, Pande I, Samuels A, Jones SD,Calin A. Low dose amitriptyline in ankylosingspondylitis: a short term, double blind, placebocontrolled study. J Rheumatol1997;24(11):2158-61.168. Maksymowych WP, Jhangri GS,Fitzgerald AA, LeClercq S, Chiu P, Yan A, <strong>et</strong>al. A six-month randomized, controlled, doubleblind,dose-response comparison ofintrav<strong>en</strong>ous pamidronate (60 mg versus 10mg) in the treatm<strong>en</strong>t of nonsteroidalantiinflammatory drug-refractory ankylosingspondylitis. Arthritis Rheum 2002;46(3):766-73.169. Grover R, Shankar S, Aneja R, MarwahaV, Gupta R, Kumar A. Treatm<strong>en</strong>t of ankylosingspondylitis with pamidronate: an op<strong>en</strong> labelstudy [l<strong>et</strong>ter]. Ann Rheum Dis 2006;65(5):688-9.170. Soriano ER, McHugh NJ. Therapies forperipheral joint disease in psoriatic arthritis. Asystematic review. J Rheumatol2006;33(7):1422-30.HAS / Service <strong>des</strong> Bonnes pratiques professionnelles <strong>et</strong> Service Évaluation médico-économique <strong>et</strong>santé publique - septembre 2008-215 -

logo

Produits

Ressources

Entreprises

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!